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Abstract This study describes the biochemical characterisation
of the catalytic domain of membrane-type 6 matrix metallopro-
teinase (MT6-MMP, MMP25, leukolysin). Its activity towards
synthetic peptide substrates, components of the extracellular
matrix and inhibitors of MMPs was studied and compared with
MT1-MMP, MT4-MMP and stromelysin-1. We have found
that MT6-MMP is closer in function to stromelysin-1 than MT1
and MT4-MMP in terms of substrate and inhibitor specificity,
being able to cleave type-IV collagen, gelatin, fibronectin and
fibrin. However, it differs from stromelysin-1 and MT1-MMP in
its inability to cleave laminin-I, and unlike stromelysin-1 cannot
activate progelatinase B. Our findings suggest that MT6-MMP
could play a role in cellular migration and invasion of the
extracellular matrix and basement membranes and its activity
may be tightly regulated by all members of the TIMP
family. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Matrix metalloproteinases (MMPs) are a family of zinc de-
pendent endopeptidases which are involved in connective tis-
sue degradation in physiological and pathological events such
as wound healing, angiogenesis, tumour growth and metasta-
sis and arthritis to name but a few [1,2]. The MMPs can be
broadly split into groups of enzymes termed stromelysins,
gelatinases, collagenases and membrane-type MMPs based
on di¡erences in structure and substrate speci¢city [1]. The
membrane-type MMPs can also be subdivided into two
groups; the type-I transmembrane and the glycosylphospha-
tidylinositol (GPI)-anchored proteases.
MT1, 2, 3 and 5 (MMP14, 15, 16 and 24) are all type-I
transmembrane proteins with a short cytoplasmic tail which
has been shown in MT1-MMP to be required for localisation
at invadopodia [3]. These enzymes have the ability to degrade
many matrix components including type-I^IV collagen, gela-
tin, laminin, ¢bronectin and ¢brin [4,5]. The phenotype of the
MT1-MMP knock-out mouse suggests that it may play a
major role in collagenolysis [6], which is supported by a recent
in vivo study of Hotary et al. [7]. The MT-MMPs were able to
activate progelatinase A and MT1-MMP was shown to acti-
vate procollagenase-3 (MMP2 and MMP13, respectively), ei-
ther in vitro or in vivo [8^13]. These enzymes are inhibited by
tissue inhibitor of metalloproteinase (TIMP)-2, which in com-
plex with MT1-MMP also acts as a progelatinase A receptor,
potentiating the activation process [14], and by TIMP-3 but
largely not by TIMP-1 ([9], Fox and Murphy, unpublished
observations).
The second sub-group of MT-MMPs consists of enzymes
which are attached to the membrane via a covalent link to
GPI. This sub-group includes MT4 and MT6-MMP (MMP17
and MMP25) [15,16]. The best characterised to date, MT4-
MMP, has far less similarity with the other MT-MMPs at the
structural and functional level and appears to be predomi-
nantly expressed in leukocytes as well as tumour cell lines
[17^19]. MT4-MMP is very limited in its ability to degrade
most ECM components examined to date [20]. Equally it does
not have the ability to activate progelatinase A or procolla-
genase-3 [20,21]. Currently, the known substrates of MT4-
MMP include ¢brinogen, ¢brin and proTNFK [20]. MT6-
MMP or leukolysin (MMP25) is a recently identi¢ed member
of the MT-MMPs expressed almost exclusively in the normal
adult in peripheral blood leukocytes and many brain tumours
[22,23]. Primary sequence alignments with the rest of the
MMP family, in particular the catalytic domains, have shown
that its closest sequence similarity is with MT4-MMP
(MMP17, 65% identity, 77% similarity) followed by MT1-
MMP (MMP14, 47% identity, 70% similarity) and stromely-
sin-1 (MMP3, 44% identity, 68% similarity) with almost equal
similarity. This raises the interesting question to what extent it
has similarity to these enzymes at the functional level. To date
it has been shown that MT6-MMP, like MT4-MMP, is either
very poor at, or unable to, activating progelatinase A and
does not participate in ectodomain shedding of proTGF-K,
HER-2 or proHB-EGF [16,22].
In this work we describe the expression and puri¢cation of
recombinant active MT6-MMP catalytic domain which has
enabled us to characterise its speci¢city towards peptides,
extracellular matrix components and TIMPs. Our results sug-
gest that MT6-MMP is much closer, although not identical to,
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stromelysin-1 in function than MT4-MMP or MT1-MMP and
may play a role in peripheral blood leukocyte invasion of the
extracellular matrix and contribute to the metastasis and
growth of brain tumours.
2. Materials and methods
2.1. Subcloning and isolation of the human proMT6-MMP catalytic
domain
The proMT6-MMP catalytic domain was subcloned from the hu-
man cDNA clone PI-4 in pBluescript by polymerase chain reaction
using primers 5P-AAAACTCGAGGGCGCAGGACGTGAGCCT-
GGGCGTG-3P and 5P-AAAAGAATTCAAGCCAGGGGTTTCCT-
TGTGGGC-3P which contained restriction sites for XhoI and EcoRI,
enabling ligation in pRSET3b and the addition of a [His]6 tag preced-
ing the pro sequence, which was then sequenced to detect errors by
dye-deoxy terminator sequencing. The proMT6-MMP catalytic do-
main consisting of residues 26^296 (where residue 1 is the initiating
Met) was then expressed in Escherichia coli BL21 [DE3] pLysS by
induction with 0.5 mM IPTG as described previously for the MT4-
MMP pro-catalytic domain [20]. The enzyme was found to be ex-
pressed at high levels as insoluble inclusions and could be puri¢ed
under denaturing conditions in an identical manner as described for
the proMT4-MMP catalytic domain using DEAE-Sepharose [20]. The
solubilised protein was then further puri¢ed by nickel a⁄nity chro-
matography on Ni NTA-agarose. Refolding of the puri¢ed enzyme
was achieved by rapid dilution in 50 mM Tris^SO4, 100 mM Na2SO4,
10 mM CaSO4, 0.1 mM ZnSO4, 10% glycerol, 0.1% Brij 35, pH 8.0,
with the ¢nal protein concentration estimated to be 0.1 mg ml31, for
18 h at 4‡C. To remove aggregates, the enzyme was then centrifuged
at 10 000Ug prior to reducing SDS^PAGE analysis and storage in
aliquots at 380‡C.
2.2. Characterisation of activity of proMT6-MMP catalytic domain
Activity of the MT6-MMP catalytic domain was measured in assay
bu¡er (50 mM Tris^HCl, 150 mM NaCl, 10 mM CaCl2, 0.05% Brij,
pH 7.5) at 25‡C at all times. The concentration of native, active
enzyme after refolding was determined as described by Murphy and
Willenbrock [24] by active site titration with TIMP-1, following inhi-
bition of hydrolysis of 1 WM (7-methoxycoumarin-4-yl)acetyl (Mca)-
PLGL-Dpa-AR-NH2 in 2.5 ml assay bu¡er using a Perkin-Elmer
LS50b £uorimeter. For calculation of kcat/KM for quenched £uores-
cent substrates, the activity of 0.5 nM MT6-MMP catalytic domain in
2.5 ml assay bu¡er was followed by monitoring hydrolysis of Mca-
PLGL-Dpa-AR-NH2, Mca-PLA-Nva-Dpa-AR-NH2 and Mca-SPLA-
QAVRSSSRK(2,4-dinitrophenyl (Dnp))-NH2 where [S]IKM and kobs
was observed to follow an apparent linear relationship with respect to
[S] ([S]6 1.5 WM). In the case of Mca-SPLAQAVRSSSRK(Dnp)-
NH2, C18 reversed phase-high performance liquid chromatography
(RP-HPLC) analysis showed that there was more than one cleavage
site. For identi¢cation of the cleavage sites the products were puri¢ed
by RP-HPLC prior to analysis by matrix-assisted laser desorbing
ionising time of £ight mass spectrometry. For the calculation of the
apparent KI (K
app
I ) for hydroxamic acid peptide analogue inhibitors
Ro31-9790 (Roche Molecular Biochemicals, Wellwyn City Gardens,
UK) and CT-1746 (CelltechChiroscience, Slough, UK), 0.5 nM MT6-
MMP catalytic domain in 2.5 ml was incubated with 0^100 nM hy-
droxamate inhibitor for 30 min at 25‡C, which allowed the enzyme^
inhibitor complex to reach equilibrium, prior to the addition of 1 WM
Mca-PLGL-Dpa-AR-NH2. Analysis of the progress curves of hydro-
lysis allowed calculation of KappI using the equation describing com-
petitive tight binding inhibition [25]. As the catalytic domain of MT6-
MMP was found to be unstable for prolonged periods of time, like
that of MT4-MMP [20], KappI for TIMPs could only be calculated for
comparison of relative a⁄nities with MT1-MMP, MT4-MMP and
stromelysin-1. The MT6-MMP catalytic domain was incubated at
0.5 nM in 100 Wl assay bu¡er at 25‡C with TIMP-1, -2 or -3 at
0^50 nM for 2 h. This was then diluted to 2.5 ml with assay bu¡er
for 2 h before activity monitored by the addition of 1 WM Mca-PLA-
Nva-Dpa-AR-NH2. K
app
I was calculated using the equation describ-
ing competitive tight binding inhibition [25].
Macromolecular substrates for the studies of activity of MT6-MMP
catalytic domain were obtained or prepared as follows: stromelysin-1,
gelatinase B, collagenase-2 and MMP19 were prepared as described
previously [26,27]. Fibrinogen puri¢ed from human plasma was ob-
tained from Calbiochem. Type-IV collagen prepared from human
placenta was a kind gift from Roche Diagnostics GmbH. Fibronectin
from human plasma, thrombin, TPCK-treated trypsin and laminin-I
were obtained from Sigma (Poole, UK). Mouse anti-human mono-
clonal antibodies to ¢bronectin were obtained from Gibco-BRL.
Type-I gelatin was prepared from rat skin type-I collagen [4]. Controls
were run without enzyme in assay bu¡er and the reactions were
stopped by the addition of reducing SDS^PAGE bu¡er and storage
on ice prior to analysis. Activity of MT6-MMP and stromelysin-1
could be inhibited by the addition of 1,10-phenanthroline. Fibronectin
fragments generated by MT6-MMP and stromelysin-1 were further
analysed by Western blot using monoclonal antibodies speci¢c for
the heparin, cell and gelatin binding domains [4]. Fibrin gel was pre-
pared by clotting ¢brinogen with thrombin as previously described
[20]. Activation of recombinant progelatinase B or procollagenase-2
was followed by incubation of 5 Wg pro-enzyme with 40 ng MT6-
MMP catalytic domain or 80 ng stromelysin-1 before analysis on
reducing SDS^PAGE.
3. Results and discussion
3.1. Expression and refolding of the recombinant
proMT6-MMP catalytic domain
On induction with IPTG, the proMT6-MMP catalytic do-
main was found to be highly expressed in E. coli from
pRSETB as insoluble inclusions, as reported for other
MMP catalytic domains. Equally, on solubilisation with 8 M
urea, the pro-catalytic domain could be puri¢ed under
denaturing conditions on DEAE-Sepharose to give a major
band at the expected mass with a number of degradation
products. This material was further puri¢ed on a Ni NTA-
agarose a⁄nity column and then refolded using the protocol
established for the proMT4-MMP catalytic domain [20] (Fig.
1, lane 1). The refolded enzyme was found to show activity
towards the quenched £uorescent substrate Mca-PLGL-Dpa-
AR-NH2, however, unlike the proMT4-MMP catalytic do-
main, incubation with 1 mM 4-amino phenylmercuric acetate
or 10 Wg ml31 TPCK-treated trypsin did not result in an
increase in activity of the refolded material. Examination by
SDS^PAGE showed that the refolded material consisted of
three forms approximating the expected mass of the pro, in-
termediate and active form of the enzyme and a smaller frag-
ment at 17 kDa which is probably a degradation product (Fig.
1, lane 3). Gelatin zymography showed that only the 25 kDa
band had any signi¢cant activity although clearance of gelatin
was poor (data not shown). Treatment with trypsin did not
Fig. 1. Coomassie blue-stained reducing SDS^PAGE gel of: lane 1,
[His]6-proMT6-MMP catalytic domain puri¢ed from insoluble inclu-
sions by DEAE-Sepharose and Ni NTA-agarose under denaturing
conditions. Lane 2, material from lane 1 refolded at a total protein
concentration of 100 Wg ml31 and then centrifuged at 20 000Ug for
30 min. Lane 3, material refolded but not centrifuged.
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alter the mobility of the three forms on SDS^PAGE (not
shown). After centrifugation at 10 000Ug to remove aggre-
gates, only the 25 kDa and 17 kDa forms were seen to remain
on analysis by SDS^PAGE of the supernatant (Fig. 1, lane 2)
and greater than 95% of activity towards the substrate Mca-
PLGL-Dpa-AR-NH2 was found to be retained. The remain-
ing catalytic domain was also found to be resistant to trypsin
hydrolysis on inspection by SDS^PAGE and activity towards
Mca-PLGL-Dpa-AR-NH2 did not alter (data not shown).
This suggests that a large proportion of the pro-catalytic do-
main of MT6-MMP formed aggregates on folding and re-
mained proteolytically protected from autocatalytic or trypsin
processing to the active form, whereas the proportion which
folded successfully underwent autocatalytic processing to yield
a trypsin stable domain. This was not previously observed for
the other pro-catalytic domains of MT-MMPs which can be
refolded to yield stable pro-enzymes, although the stromely-
sin-like enzyme, MMP19, has also been reported to autoacti-
vate during refolding [25]. For subsequent studies the autoac-
tivated form of the catalytic domain was used.
Table 1
Comparison of kcat/KM calculated at 25‡C, pH 7.5 for MT6-MMP with other MMPs for quenched £uorescent peptide substrates
Substrate kcat/KMU104 M31 s31
Stromelysin-1 (MMP3) MT1-MMP (MMP14) MT4-MMP (MMP17) MT6-MMP (MMP25)
Mca-PLGL-Dpa-AR-NH2 0.16 2.1 2.4 3.8
Mca-PLA-Nva-Dpa-AR-NH2 1.4 0.86 3.0 8.3
Mca-SPLAQAVRSSSRK(Dnp)-NH2 NC NH 3.5 NC
NH denotes ‘not hydrolysed’ and NC ‘not calculated’ as the substrate was not cleaved at a unique site.
Fig. 2. Coomassie blue-stained reducing SDS^PAGE gels of ECM cleavage by MT6-MMP catalytic domain and stromelysin-1. All reactions
were performed in assay bu¡er for 18 h at 25‡C. A: 40 Wg of type-I gelatin incubated in assay bu¡er alone (control) or with 250 ng active
MT6-MMP catalytic domain (MT6) or 450 ng, i.e. equi-molar, stromelysin-1 (SL-1). B: 40 Wg type-IV collagen puri¢ed form human placenta
incubated in assay bu¡er alone (control), 250 ng MT6-MMP catalytic domain (MT6) or 450 ng stromelysin-1 (SL-1). C: 20 Wg of laminin-I in-
cubated with assay bu¡er or 250 ng MT6-MMP catalytic domain. D: 20 Wg of ¢brinogen incubated in assay bu¡er alone or with 250 ng MT6-
MMP or 450 ng stromelysin-1. E: 500 Wg of X-linked ¢brin was incubated with 1 Wg of MT6-MMP or 450 ng stromelysin-1.
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3.2. Speci¢city of MT6-MMP towards peptide substrates and
inhibitors
In order to establish whether MT6-MMP is closest to MT4-
MMP, MT1-MMP or stromelysin-1 in substrate speci¢city, an
initial investigation was made by examining peptide substrate
speci¢city. Comparison of the e⁄ciency of hydrolysis of
Mca-PLGL-Dpa-AR-NH2, Mca-PLA-Nva-Dpa-AR-NH2 and
Mca-SPLAQAVRSSSRK(Dnp)-NH2 by MT6-MMP with
MT1-MMP, MT4-MMP and stromelysin-1 indicates that
MT6-MMP is closer in speci¢city to stromelysin-1. MT6-
MMP shows a clear preference for the stromelysin substrate
Mca-PLA-Nva-Dpa-AR-NH2 over the general MMP sub-
strate Mca-PLGL-Dpa-AR-NH2 (Table 1). MT6-MMP only
poorly hydrolysed a peptide consisting of the ectodomain
cleavage site of proTNFK, Mca-SPLAQAVRSSSRK(Dnp)-
NH2, with an apparent kcat/KM of 1.3U104 M31 s31, which
was more e⁄ciently hydrolysed by MT4-MMP at 3.5U104
M31 s31. Subsequent examination of the cleavage of Mca-
SPLAQAVRSSSRK(Dnp)-NH2 by MT6-MMP by RP-
HPLC indicated two cleavage sites, hence only an apparent
rate of hydrolysis could be determined from the observed
increase in hydrolysis by £uorescence. We have previously
reported that MT1-MMP cannot hydrolyse this peptide [20].
This is unlike MT4-MMP which uniquely cleaves at QsA, as
MT6-MMP instead cleaves at the same sites reported for
MMP1, 9 and MT1-MMP (in a GST fusion), at SPLAs
QAsVRSSSRK [4,28]. To further investigate the character-
istics of the primed side of the active site of MT6-MMP,
a⁄nities for two competitive hydroxamic acid inhibitors
were examined. Ro31-9790 is most potent towards gelatinases,
MT-MMPs and collagenases but is a poor inhibitor of stro-
melysins. In contrast CT-1746 is a potent inhibitor of strome-
lysins, gelatinases and MT-MMPs but not collagenases [20].
The approximate 10-fold di¡erence in a⁄nity of MT6-MMP
for these inhibitors is comparable to the di¡erence seen with
stromelysin-1 and therefore suggests that the primed side of
the active site is more stromelysin-like in character (Table 2).
In contrast MT1 and 4-MMP did not show any preference for
this inhibitor, similar to the gelatinases (Table 2 and [20]).
3.3. Speci¢city of MT6-MMP for TIMPs
The catalytic domain of MT6-MMP was found to be well
inhibited by TIMP-1, although it was e¡ectively titrated by
TIMP-2 and -3 where KappI was estimated to be I[E] at
which activity could be detected, hence the complex can be
considered irreversible under the conditions of the experiment
(Table 2). This again di¡ers from MT1-MMP which is also
inhibited by TIMP-2 and -3 but is very poorly inhibited by
TIMP-1, and MT4-MMP which is titrated by TIMP-1 but has
lower a⁄nity for TIMP-2 and -3 (Table 2). These results
Table 2
KappI for MT6-MMP and other MMPs for hydroxamate peptide analogue inhibitors and TIMPs calculated at 25‡C, pH 7.5
Inhibitor KappI (U10
39 M)
Stromelysin-1 (MMP3) MT1-MMP (MMP14) MT4-MMP (MMP17) MT6-MMP (MMP25)
CT-1746 10.9 1.1 4.7 0.3
Ro31-9790 119 3.3 2.3 6
TIMP-1 I0.2 NI I0.07 0.02
TIMP-2 I0.2 I0.002 0.4 I0.002
TIMP-3 I0.2 0.06 0.2 I0.002
Where KappI was estimated to be signi¢cantly lower than [E] at which activity of uninhibited enzyme could be detected, and the inhibitor still
titrated the enzyme, values have ‘I’ in front to indicate the KappI quoted is a maximal estimate. NI indicates ‘not inhibited’ at concentrations
of [I] unless in the WM range or greater. Values for MT1 and 4-MMP are taken from [20]. Values for stromelysin-1 are taken from [20] for the
hydroxamate inhibitors and [29] for the TIMPs.
Fig. 3. Degradation of ¢bronectin. A: Coomassie blue-stained reducing SDS^PAGE analysis of the degradation of 20 Wg ¢bronectin incubated
in assay bu¡er overnight (18 h) at 25‡C alone (control), with 250 ng MT6-MMP catalytic domain (MT6) or 450 ng stromelysin-1 (SL-1).
B: Immunoblot of the degradation products produced in the reactions shown in A probed with mouse anti-human monoclonals to the heparin,
cell and gelatin binding domains of ¢bronectin, visualised using the enhanced chemiluminescence method. The blot is split in two as indicated
as di¡erent exposure times were required to detect the larger and smaller products. Arrows indicate the major products detected.
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suggest that activity of MT6-MMP may require tight regula-
tion in vivo.
3.4. Hydrolysis of extracellular matrix components by the
MT6-MMP catalytic domain
As the peptide and hydroxamate inhibitor speci¢city of
MT6-MMP suggested that it is a stromelysin-like enzyme,
hydrolysis of ECM components known to be substrates for
stromelysin-1 [1] by MT6-MMP was also examined. By fol-
lowing cleavage of ECM components using equal amounts of
active MT6-MMP and stromelysin-1, as determined by active
site titration by TIMP-1, approximate comparisons of the rel-
ative ability of each enzyme to cleave macromolecular sub-
strates could be made. Exceptionally, MT6-MMP was able to
cleave gelatin at a comparable rate to stromelysin-1 (data not
shown). However, the products generated by MT6-MMP did
not have the same mobility on SDS^PAGE as those generated
by stromelysin-1 (Fig. 2A). Like stromelysin-1, MT6-MMP
was able to hydrolyse type-IV collagen, although after 24 h
at 25‡C, the products were of a signi¢cantly larger size at the
same enzyme:substrate ratio (Fig. 2B). A comparison of the
relative abilities of the two enzymes to cleave this substrate
showed MT6-MMP to be in the order of 2^3-fold faster at
degrading type-IV collagen (data not shown). This activity of
MT6-MMP may be of particular signi¢cance in view of the
low temperature at which cleavage is seen. Recent studies
have shown that gelatinase A or B (previously named 72
and 92 kDa type-IV collagenase) cleave type-IV collagen in
a temperature sensitive manner, with little or no cleavage
occurring at temperatures below 30‡C, whereas stromelysin-
1 e⁄ciently cleaves type-IV collagen at 25‡C. The suggestion
is that solubilised type-IV collagen is not always wholly native
at temperatures higher than 30‡C and has led to the conclu-
sion that the type-IV collagenase activity of gelatinase A and
B may not be of such signi¢cance in vivo [30]. This makes the
activity of MT6-MMP towards this component of the base-
ment membrane particularly interesting. However, the activity
of MT6-MMP does not extend to all components of the base-
ment membrane as MT6-MMP was not able to show any
signi¢cant activity towards laminin-I (Fig. 2C). MT6-MMP
was able to cleave the AK and BL chain of ¢brinogen (Fig.
2D) and a comparison of the rate of cleavage with stromely-
sin-1 showed that they were producing the same cleavage
pattern although MT6-MMP was approximately 3-fold slower
(data not shown). In contrast, the catalytic domain of MT6-
MMP appeared more e¡ective at hydrolysing cross-linked ¢-
brin than stromelysin-1, generating fragments of 50 and 40
kDa, whereas stromelysin-1 had only generated the 50 kDa
fragment after 18 h (Fig. 2E and data not shown). On exam-
ining the cleavage of another ECM component, ¢bronectin,
MT6-MMP and stromelysin-1 appeared to generate a variety
of di¡erent fragments when visualised by Coomassie blue
after SDS^PAGE (Fig. 3A). Analysis of the cleavage after
an 18 h incubation, using monoclonal antibodies to the cell,
gelatin and heparin binding domains of ¢bronectin, revealed
that MT6-MMP and stromelysin-1 both predominantly re-
lease the heparin binding domain, although MT6-MMP ap-
peared less e¡ective over the same time scale (Fig. 3B). As a
study by Hotary et al. [7] has recently shown that the MT-
MMPs and not the soluble MMPs are the most e¡ective at
aiding cellular invasion of basement membranes, the ability of
MT6-MMP to degrade components of the ECM and in par-
ticular the basement membrane protein type-IV collagen may
aid the extravasation of neutrophils and the growth and meta-
stasis of brain tumours.
3.5. Activation of progelatinase B (MMP9), procollagenase-2
(MMP8)
As stromelysin-1 has been shown to activate progelatinase
B in vitro, the ability of MT6-MMP to activate progelatinase
B was also investigated. MT6-MMP was not found to process
progelatinase B, nor was it able to complete the processing of
the intermediate form generated by MMP19 ([27], data not
shown). Pei described that mRNA for MT6-MMP was found
highly expressed in neutrophils [23], hence activation of neu-
trophil procollagenase-2 was also examined and again MT6-
MMP was unable to process or activate this pro-enzyme (data
not shown).
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